8-K: Elevation Oncology Completes Acquisition by Concentra Biosciences, Shares to Delist

Elevation Oncology, Inc. has finalized its merger with Concentra Biosciences, LLC's subsidiary, resulting in the company becoming a private entity and its shares being delisted from Nasdaq.

Summary

• Elevation Oncology, Inc. (ELEV) completed its merger with Concentra Merger Sub VI, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC, on July 23, 2025.
• The merger followed a successful tender offer where 39,773,172 shares, representing approximately 67.09% of outstanding shares, were validly tendered and not withdrawn, satisfying the minimum tender condition.
• Shareholders received $0.36 in cash per share plus one non-transferable contractual contingent value right (CVR) per share.
• Outstanding Company Stock Options with an exercise price less than $0.36 were accelerated and cancelled for cash (Cash Amount minus exercise price) and one CVR per share; options with an exercise price equal to or greater than $0.36 were cancelled for no consideration.
• Company Restricted Stock Units (RSUs) were accelerated, cancelled, and holders received $0.36 in cash and one CVR per unit.
• Holders of 22,050,000 outstanding warrants received cash equal to their Black Scholes Value.
• The company's common stock was suspended from trading on Nasdaq effective before the opening of trading on July 23, 2025, and will be delisted and deregistered.
• Elevation Oncology, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive from a transactional perspective, as the merger was completed as planned, providing a defined exit for shareholders with a cash component and potential future upside via CVRs. However, it signifies the end of the company's independent public existence, which could be seen as negative for those who preferred its standalone status. The low cash price per share ($0.36) is a significant factor.

Positives

• The tender offer successfully met the minimum tender condition, allowing the merger to proceed as planned.
• Shareholders received a cash payment and a contingent value right, offering immediate value and potential future upside.
• Equity awards (in-the-money options and RSUs) were accelerated and converted into cash and CVRs, providing liquidity to employees.

Negatives

• Elevation Oncology, Inc. ceased to be an independent, publicly traded company, becoming a wholly-owned subsidiary.
• The company's common stock was delisted from Nasdaq and will be deregistered, eliminating public trading liquidity.
• Company Stock Options with an exercise price equal to or greater than the $0.36 cash amount were cancelled for no consideration, resulting in a loss for those holders.

Risks

• The contingent value rights (CVRs) are non-transferable, limiting liquidity and the ability of holders to realize their value until potential future payments, which are subject to specific terms and conditions.
• Delisting and deregistration remove the company's shares from public trading, significantly reducing liquidity for any remaining shareholders (though most shares were tendered).
• The value of the CVRs is contingent and uncertain, representing potential payments rather than guaranteed amounts.

Future Outlook

The company will cease to be a publicly reporting entity, with its shares delisted from Nasdaq and registration terminated with the SEC. Future financial performance and strategic direction will be determined by Concentra Biosciences, LLC, as Elevation Oncology is now a wholly-owned subsidiary. The value of the contingent value rights (CVRs) will depend on future events and conditions as outlined in the CVR Agreement.

Management Comments

• Resignations of directors were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies, or practices.

Industry Context

This acquisition reflects a trend of consolidation within the biotechnology and pharmaceutical sectors, where larger entities or private equity firms acquire smaller, often clinical-stage, companies. Such mergers can provide an exit strategy for investors in companies that may face significant capital requirements or development hurdles, integrating their assets or pipelines into a broader portfolio. The use of CVRs is a common mechanism in biotech acquisitions to bridge valuation gaps and share future success or risk related to specific drug candidates or milestones.

Comparison to Industry Standards

• The acquisition price of $0.36 per share plus a CVR is specific to Elevation Oncology's valuation and pipeline, which is not directly comparable without detailed financial and clinical data of similar-stage oncology companies.
• The use of a Contingent Value Right (CVR) is a standard mechanism in biotech mergers, particularly when there is uncertainty around the future value of pipeline assets. Companies like Celgene (acquired by Bristol-Myers Squibb) and Array BioPharma (acquired by Pfizer) have also utilized CVRs in their acquisition structures, though the specific terms and underlying assets vary significantly.
• The tender offer acceptance rate of 67.09% is sufficient to complete the merger under Delaware law (Section 251(h)), which typically requires a majority of outstanding shares to be tendered, making it a successful outcome for the acquirer's strategy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $0.36 cash per share and one non-transferable CVR per share, providing a defined exit value and potential future payments, but losing public trading liquidity.
• Employees (with equity awards): In-the-money stock options and restricted stock units were accelerated and converted into cash and CVRs, providing a liquidity event.
• Management: Key executives (Interim CEO/CFO) were terminated with severance packages, and new management from Concentra Biosciences was appointed, indicating a complete change in leadership.

Next Steps

• The Surviving Corporation intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC to terminate registration of shares under Section 12(g) of the Exchange Act.
• The Surviving Corporation intends to suspend reporting obligations under Section 13 and 15(d) of the Exchange Act.
• Future potential payments to CVR holders will occur based on the terms and conditions of the CVR Agreement.

Key Dates

Recommendation

The company has completed its acquisition and is being delisted from public exchanges. For any remaining shareholders who have not yet tendered their shares, the recommendation is to sell or tender to realize the offer price and CVR, as the stock will no longer be publicly traded and will lose liquidity. For new investors, the stock is no longer available for purchase on public markets.

Keywords

Elevation Oncology, Concentra Biosciences, Merger, Acquisition, Tender Offer, Delisting, Deregistration, Contingent Value Right, Biotechnology, Pharmaceuticals, Corporate Action